MX2023013711A - Composicion farmaceutica que comprende enavogliflozina para usarse para la prevencion o el tratamiento de diabetes mellitus en animales de la familia canidae. - Google Patents

Composicion farmaceutica que comprende enavogliflozina para usarse para la prevencion o el tratamiento de diabetes mellitus en animales de la familia canidae.

Info

Publication number
MX2023013711A
MX2023013711A MX2023013711A MX2023013711A MX2023013711A MX 2023013711 A MX2023013711 A MX 2023013711A MX 2023013711 A MX2023013711 A MX 2023013711A MX 2023013711 A MX2023013711 A MX 2023013711A MX 2023013711 A MX2023013711 A MX 2023013711A
Authority
MX
Mexico
Prior art keywords
enavogliflozin
animal
pharmaceutical composition
diabetes mellitus
treating diabetes
Prior art date
Application number
MX2023013711A
Other languages
English (en)
Inventor
Joon Seok Park
Ju Mi Han
Wan Huh
Hyun Woo Lim
Ji Soo Choi
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of MX2023013711A publication Critical patent/MX2023013711A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica para la prevención o tratamiento de la diabetes mellitus en un animal de la familia Canidae, que incluye como principio activo la enavogliflozina. La composición farmacéutica de la presente invención, que incluye enavogliflozina como un ingrediente activo, muestra un excelente efecto de control del nivel de glucosa en sangre y, por lo tanto, puede usarse de manera efectiva para tratar la diabetes mellitus en un animal de la familia Canidae.
MX2023013711A 2021-05-21 2022-05-20 Composicion farmaceutica que comprende enavogliflozina para usarse para la prevencion o el tratamiento de diabetes mellitus en animales de la familia canidae. MX2023013711A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20210065733 2021-05-21
PCT/KR2022/007206 WO2022245171A1 (ko) 2021-05-21 2022-05-20 이나보글리플로진을 포함하는 개과 동물의 당뇨병 예방 또는 치료용 약학 조성물

Publications (1)

Publication Number Publication Date
MX2023013711A true MX2023013711A (es) 2024-01-16

Family

ID=84141513

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013711A MX2023013711A (es) 2021-05-21 2022-05-20 Composicion farmaceutica que comprende enavogliflozina para usarse para la prevencion o el tratamiento de diabetes mellitus en animales de la familia canidae.

Country Status (11)

Country Link
US (1) US20240245641A1 (es)
EP (1) EP4342476A1 (es)
JP (1) JP2024518644A (es)
KR (1) KR20220157906A (es)
CN (1) CN117460517A (es)
AU (1) AU2022276995A1 (es)
BR (1) BR112023024125A2 (es)
CA (1) CA3219572A1 (es)
MX (1) MX2023013711A (es)
WO (1) WO2022245171A1 (es)
ZA (1) ZA202310748B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240107660A (ko) * 2022-12-30 2024-07-09 주식회사 대웅제약 이나보글리플로진 및 메트포르민을 포함하는 약학 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110117841A (ko) * 2010-04-22 2011-10-28 황우석 Pepck 과발현 형질전환 복제 개과 동물 및 이의 생산방법
CN103180435A (zh) * 2010-08-31 2013-06-26 库克通用生物技术有限责任公司 用于治疗动物疾病的全身的同种异体干细胞疗法
ES2719656T3 (es) 2011-06-01 2019-07-11 Green Cross Corp Derivados de difenilmetano novedosos como inhibidores del SGLT2
KR20220097538A (ko) * 2014-01-23 2022-07-07 베링거잉겔하임베트메디카게엠베하 개과 동물에서 대사 장애의 치료
JP6682621B2 (ja) * 2015-08-27 2020-04-15 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーBoehringer Ingelheim Vetmedica GmbH Sglt−2阻害剤含む液体医薬組成物

Also Published As

Publication number Publication date
CA3219572A1 (en) 2022-11-24
ZA202310748B (en) 2024-07-31
BR112023024125A2 (pt) 2024-01-30
US20240245641A1 (en) 2024-07-25
CN117460517A (zh) 2024-01-26
WO2022245171A1 (ko) 2022-11-24
JP2024518644A (ja) 2024-05-01
KR20220157906A (ko) 2022-11-29
EP4342476A1 (en) 2024-03-27
AU2022276995A1 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
PH12015501009A1 (en) A composition for treating diabetes or diabesity comprising oxyntomodulin analog
NZ608829A (en) Pharmaceutical composition comprising an sglt2-inhibitor, methods for treating and uses thereof
ZA202310748B (en) Pharmaceutical composition for preventing or treating diabetes mellitus in animal of family canidae, comprising enavogliflozin
NZ701559A (en) Compositions comprising povidone-iodine
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
MX2013004699A (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos.
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
GB2476202A (en) Novel choline cocrystal of epalrestat
WO2011049327A3 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
WO2018169282A3 (ko) Atpif1을 함유하는 당뇨 치료용 약학조성물
MX2022014309A (es) Compuestos de insulina acilada de accion temporal prolongada.
WO2021046315A3 (en) Inhibitors of encephalitic alphaviruses
MX2023007080A (es) Metodo para el tratamiento de la fibrosis.
MX2021009219A (es) Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria.
EA200800338A1 (ru) Профилактика и лечение офтальмологических осложнений диабета
HK1109563A1 (en) Protein hydrolysate with antidiabetic effect
WO2020016655A3 (en) Treatment of neuropathy with dna constructs expressing igf-1 isoforms
MY197721A (en) Composition and uses thereof
WO2010044637A3 (ko) 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
BR112022004038A2 (pt) Composições veterinárias granulares palatáveis
WO2019035646A8 (ko) 세포사멸 수용체 저해제를 유효성분으로 포함하는 cx3cl1 케모카인 과발현으로 인한 질환 예방 또는 치료용 조성물
MX2014001855A (es) Nuevo compuesto aislado de quamoclit, y una composicion para la prevencion o el tratamiento de la diabetes que contiene el compuesto como un ingrediente activo.
EP4327815A3 (en) Probiotics for regulating blood glucose
ATE529127T1 (de) Pharmazeutische zusammensetzung mit arazym zur prävention von leberfunktionsstörung
WO2020018058A3 (en) The injectable micronized human insulin